Developmental Projects funded from 2003 – present | |||
PI | Institution | Project Title | |
Year 1 (2003-04) | |||
Iliopoulos, Othon | MGH | Functional Analysis of the BHD Tumor-Suppressor Protein | |
Libermann, Towia Jones, Jon | BIDMC | Genetic Classification of Clear Cell RCC | |
Michaelson, Dror | MGH | The Role of Bone-Targeted Therapy with Zoledronic Acid in Metastatic RCC | |
Panka, David Mier, James | BIDMC | Potential synergy between sorafenib and AKT inhibitors against RCC* | |
Year 2 (2004-05) | |||
Haber, Dan Rivera, Miguel | MGH | Identification of Novel Genes in Sporadic Wilms Tumor* # | |
Artavonis-Tsakonas, Spyros | MGH | A Genetic Model for Target identification in VHL-HIF Signaling | |
Signoretti, Sabina Moch, Holger | BWH | Molecular Analysis of RCC Using Single Nucleotide Polymorphisms (SNP) Arrays# | |
Alper, Seth | BIDMC | Role of Carbonic Anhydrase IX in Proliferation and Metastasis of RCC | |
Dabora, Sandra | BWH | A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas | |
Olumi, Aria | BIDMC | Pro-apoptotic TRAIL-directed Therapies for the Treatment of Advanced RCC | |
Ross, Robert Weissleder, Ralph | DFCI MGH | Comparison of pathologic microvessel density and monocrystalline iron oxide nanoparticle-enhanced MRI in evaluationg tumor vascularity in pts undergoing Nx for RCC | |
Year 3 (2005-06) | |||
Alsop, David Rofsky, Neil | BIDMC | ASL MRI Blood Flow for Monitoring Response to Anti-angiogenic Therapy* | |
Avigan, David Rosenblatt, Jacalyn | BIDMC | Phenotypic and Functional Characteristics of Human T cells Stimulated ex vivo with DC/tumor Fusion Cells and Expanded with CD3, CD28 Ab* | |
Libermann, Towia Zerbini, Luiz | BIDMC | The Tyrosine Kinase Receptor Axl, a Novel Therapeutic Target in RCC# | |
Seth, Pankaj | BIDMC | Role of Angiopoietin like 4 (ANGPTL4) as a VEGF Independent Pro-angiogenesis Factor | |
Year 4 (2006-07) | |||
Marasco, Wayne Wu, Anna | DFCI UCLA | PET Evaluation of RCC Metastases using High-affinity Human Anti-CAIX Monoclonal Antibody with Optimized Pharmacokinetic Properties | |
Signoretti, Sabina | BWH | Development of Mouse Orthotopic Xenografts of Human RCC# * | |
Frank, David | DFCI | STAT-Mediated Modulation of HIF Signaling: Molecular Strategies for the Treatment of RCC# | |
Lenahan (Zarwan), Corine Rosenblatt, Jacalyn Avigan, David | BIDMC | The effect of Anti-angiogenic Drugs on Tumor Mediated Immune Suppression and Response to the DC/RCC Fusion Vaccine* | |
Iliopoulos, Othon | MGH | A Drosophila Genetic Screen for Target Identification in VHL-HIF Signaling | |
Goldberg, Nahum Mier, James | BIDMC | Mechanism of RCC Resistance to VEGFR Blockade with Sorafenib* | |
Year 5 (2007-08) | |||
Panka, David Cho, Daniel Mier, James | BIDMC | Potential Synergy Between Triterpenoids and NADPH Oxidase Inhibitors in the Treatment of RCC | |
Sukhatme, Vikas | BIDMC | LDH-A Inhibitors for the Treatment of Fumarate Hydratase (FH) Associated Hereditary Leiomyomatosis and RCC (HLRCC) | |
Zimmer, Michael | MGH | Identification of Novel Proteins that inhibit HIF mRNA Translation | |
Libermann, Towia Sukhatme, Vikas | BIDMC | Identification of new drugs for treatment of RCC patients using Gene Signatures and the Connectivity Map Database | |
Extension Year (2008-09) | |||
Cho, Eunyoung Choueiri, Toni | HSPH DFCI | Analgesic Use and the Risk of RCC | |
Bhatt, Rupal | BIDMC | Role of defects in IFNg signaling in escape from VEGFR inhibition | |